

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
20 April 2006 (20.04.2006)

PCT

(10) International Publication Number
WO 2006/040178 A1

(51) International Patent Classification:

C07D 311/04 (2006.01) A61K 31/47 (2006.01)
C07D 215/38 (2006.01) A61K 31/35 (2006.01)
C07C 211/19 (2006.01) A61P 25/16 (2006.01)
A61K 31/13 (2006.01)

(74) Agent: REITSTÖTTER, KINZEBACH & PARTNER
(GbR); Ludwigsplatz 4, 67059 Ludwigshafen (DE).

(21) International Application Number:

PCT/EP2005/011091

(22) International Filing Date: 14 October 2005 (14.10.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/618,776 14 October 2004 (14.10.2004) US
60/711,942 26 August 2005 (26.08.2005) US

(71) Applicant (for all designated States except US): ABBOTT
GMBH & CO. KG [DE/DE]; Max-Planck-Ring 2, 65205
Wiesbaden (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DRESCHER,
Karla [DE/DE]; Unteres Bieth 10, 69221 Dossenheim
(DE). HAUPT, Andreas [DE/DE]; Schaelzigweg 52,
68723 Schwetzingen (DE). UNGER, Liliane [DE/DE];
Wollstrasse 129, 67065 Ludwigshafen (DE). TURNER,
Sean, C. [GB/DE]; Lameystrasse 21, 68165 Mannheim
(DE). BRAJE, Wilfried [DE/DE]; Meerfeldstr. 52, 68163
Mannheim (DE). GRANDEL, Roland [DE/DE]; Birken-
weg 49, 69221 Dossenheim (DE). HENRY, Christophe
[FR/DE]; Gartenstr. 1, 68723 Schwetzingen (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY,
MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE
FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D₃ RECEPTOR



(57) Abstract: The present invention relates to aromatic compounds of the formula (I), wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical R^a and wherein Ar may also carry 1 or 2 radicals R^b; X is N or CH; Y is O, S, -CH=N-, -CH=CH- or -N=CH-; A is CH₂, O or S; E is CR⁶R⁷ or NR³; R¹ is C₁-C₄-alkyl, C₃-C₄-cycloalkyl, C₃-C₄-cycloalkylmethyl, C₃-C₄-alkenyl, fluorinated C₁-C₄-alkyl, fluorinated C₃-C₄-cycloalkyl, fluorinated C₃-C₄-cycloalkylmethyl, fluorinated C₃-C₄-alkenyl, formyl or C₁-C₃-alkylcarbonyl; R^{1a} is H, C₂-C₄-alkyl, C₃-C₄-cycloalkyl, C₃-C₄-alkenyl, fluorinated C₁-C₄-alkyl, fluorinated C₃-C₄-cycloalkyl, or R^{1a} and R² together are (CH₂)_n with n being 2 or 3, or R^{1a} and R^{2a} together are (CH₂)_n with n being 2 or 3; R² and R^{2a} are independently of each other H, CH₃, CH₂F, CHF₂ or CF₃; R³ is H or C₁-C₄-alkyl; R⁶, R⁷ independently of each other are selected from H, C₁-C₂-alkyl and fluorinated C₁-C₂-alkyl; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D₃ receptor ligand.